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Cancer surveillance, 
obesity, and potential 
bias
Although Hyuna Sung and colleagues1 
stressed caution in interpreting their 
ecological study in The Lancet Public 
Health (March, 2019),  the naive 
reader—or the media, as was the 
case2—might conclude that obesity is 
fuelling the reported disproportionate 
temporal increases in incidence of 
obesity-related cancers in young 
adults. However, there are many 
arguments against obesity as a causal 
driver. 
First,  as the accompanying 
Comment3 highlighted, the biological 
mechanisms for many early-onset 
cancers are distinct from those of late-
onset cancers. In colorectal cancer, the 
malignancy in which increases among 
young adults are most striking, 
the molecular phenotype of early-
onset cancer is often an aggressive 
consensus molecular subtype (CMS), 
such as CMS-1 or CMS-3, whereas 
obesity-related cancers generally 
follow a more canonical CMS-2 
pathway. Second, the Article by Sung 
and colleagues1 failed to demonstrate 
sex or racial specificity, which are 
hallmarks of the obesity–cancer 
relationship.4 Finally, the fundamental 
premise in age–period–cohort mode- 
lling attributes cohort effects to 
modifiable lifestyle or environmental 
factors, at the absolute rejection of 
short-term changes in population-
level genetic susceptibility. This 
method ignores the contributory role 
of epigenetic effects (for example, 
methylation), which can influence 
short-term trends. 
There is a need for a concerted effort 
from the research community to bring 
together wide-ranging disciplines 
to disentangle the causes of this 
emerging public health problem. 
The linked Comment3 advocates 
for “further close epidemiological 
monitoring”. We champion a wider 
approach, such as that captured by 
triangulation5 (the combination of 
evidence from studies that yield causal 
estimates with different potential 
sources of bias, but where these biases 
are independent), and inclusion of the 
use of non-conventional approaches, 
such as instrumental variable analyses.
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